| CAS |
No.103577-45-3 |
| 中文名称 |
兰索拉唑 |
| 英文名称 |
Lansoprazole |
| 别名 |
兰索拉唑;CV-11974-d4;兰索拉唑;南索拉唑; |
| 分子式 |
C16H14F3N3O2S |
| 分子量 |
369.36 |
| 溶解性 |
Soluble in DMSO ≥10mg/mL |
| 纯度 |
HPLC≥98% |
| 外观(性状) |
White to off-white Solid |
| 储存条件 |
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| EC |
EINECS 2017-001-1 |
| MDL |
MFCD00866873 |
| SMILES |
O=S(C1=NC2=CC=CC=C2N1)CC3=NC=CC(OCC(F)(F)F)=C3C |
| InChIKey |
MJIHNNLFOKEZEW-UHFFFAOYSA-N |
| InChI |
InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22) |
| PubChem CID |
3883 |
| 靶点 |
Proton Pump |
| 通路 |
Membrane Transporter&Ion Channel |
| 背景说明 |
Lansoprazole/AG-1749是质子泵抑制剂。 |
| 生物活性 |
Lansoprazole is an orally active proton pump inhibitor which prevents the stomach from producing acid.Lansoprazole is a Proton Pump Inhibitor and agonist of liver x receptors.[1-2] |
| In Vitro |
Lansoprazole inhibited gastric acid formation in acutely isolated gastric glands (IC??) values， 0.76 μM.[3] |
| In Vivo |
After administration of lansoprazole for 4 days， no significant alteration in the terminal elimination half-life (t1/2beta) or the mean resistance time (MRT) was detected. However， there was a significant decrease of about 13% in the area under the plasma concentration-time curve (AUC) and a significant increase of about 19% in the apparent clearance (CLapp). Lansoprazole treatment for 11 days caused a significant decrease of approximately 12% in t1/2beta and about 10% in the MRT of theophylline， although neither AUC nor CLapp showed a significant alteration. The excretion of 3-MX in the urine was significantly increased by about 20% after lansoprazole treatment for 4 and 11 days， although there was no significant alteration in the excretion of unchanged theophylline， 1，3-DMU or 1-MU. [1]Lansoprazole treatment significantly attenuated STZ and HFD -induced memory deficits， biochemical and histopathological alterations. It also prevented HFD-induced rise in the Cholesterol level. Moreover， both cholesterol-dependent as well as cholesterol-independent effects of lansoprazole appear to play a role.[2] |
| 动物实验 |
The effect of the new substituted benzimidizole Proton Pump Inhibitor， lansoprazole， on pharmacokinetics and metabolism of theophylline has been studied in healthy adults given oral lansoprazole 30 mg once daily for 11 days. On Days 4 and 11 of 300 mg aminophylline was simultaneously administered orally and blood samples for theophylline analysis were taken over 24 h. Urine samples were collected for up to 24 h and were assayed for theophylline and its major metabolites 1，3-dimethyluric acid (1，3-DMU)， 1-methyluric acid (1-MU) and 3-methylxanthine (3-MX).[1] |
| 数据来源文献 |
[1]. Kokufu， T.， et al.， Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol， 1995. 48(5): p. 391-5.
[2]. Rupinder K Sodhi， et al. Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet. PLoS One. 2013 Jul 31;8(7):e70487.
[3]. Jun Matsukawa， et al. A comparative study on the modes of action of TAK-438， a novel potassium-competitive acid blocker， and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011 May 1;81(9):1145-51. |
| 规格 |
500mg 1g |
| 单位 |
瓶 |
中文
英语
说明书下载
京公网安备 11011202000391号